Glaxosmithkline Pharmaceuticals Ltd (GLAXO)
₹2,514.30
Mkt cap
₹42,594 Cr
P/E ratio
44.30
P/B
18.76
Div yield
2.27%
ROE
45.60%
ROCE
61.40%
EPS (TTM)
₹56.76
Book value
₹134
52W range
2,103–3,197
Sector
Healthcare
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Health check
Cautious
ValuationExpensive
ProfitabilityStrong
GrowthLow
TechnicalsNeutral
52-week range
−21.35% from high₹2,514
₹2,103+19.55% from low₹3,197
Current
₹2,514.30
Prev close
₹2,519.00
Day
−0.19%
Price performance
1D
−0.19%
1W
+1.26%
1M
+6.77%
3M
+1.71%
6M
+10.64%
1Y
−20.77%
YTD
+1.23%
Financials
FRevenue, profit & margin
P/E ratio
44.3×
GLAXO is 30% above the sector median of 34.0×
GLAXO44.3×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 787 | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | |
| Expenses | 618 | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | |
| Operating Profit | 170 | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | |
| OPM % | 22% | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | |
| Other Income | 38 | 54 | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 | |
| Interest | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | |
| Depreciation | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | |
| Profit before tax | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | |
| Tax % | 30% | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | |
| Net Profit | 133 | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | |
| EPS in Rs | 7.88 | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
3 Aug '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.20% · closed higher next day 21 of last 43
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 27 Jul '23 | 9 Nov '23◦ | 12 Feb '24◦ | 17 May '24◦ | 2 Aug '24◦ | 30 Oct '24 | 14 Feb '25◦ | 13 May '25◦ | 1 Aug '25 | 6 Nov '25◦ | 9 Feb '26 | 13 May '26 |
| Earnings day | −0.08% | +1.55% | −6.86% | +3.17% | −2.00% | +1.70% | +15.97% | +3.23% | −7.15% | −0.68% | +1.30% | −1.52% |
| +1 day | −0.44% | +1.50% | −7.98% | +2.51% | −1.09% | +3.14% | +25.71% | +3.23% | −9.28% | −2.52% | +5.59% | −1.31% |
| +5 days | +0.06% | +13.70% | −2.18% | +3.24% | +2.48% | −0.69% | +30.73% | +7.01% | −16.18% | −4.84% | +4.56% | −4.17% |
| +15 days | +0.63% | +16.72% | −8.96% | +13.74% | +1.91% | −10.95% | +31.64% | +22.64% | −11.40% | −1.38% | +1.96% | −11.52% |
| +30 days | +4.29% | +24.86% | −16.82% | +14.51% | −0.76% | −13.35% | +41.56% | +16.86% | −13.42% | −2.94% | −7.04% | −3.84% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 57 Per Share | 57.00 | 29 May '26 | 29 May '26 |
Shareholding
Sas of Jun 202675.00%Promoter
Promoters75.00%
FIIs4.79%0.17
DIIs7.81%0.13
Public12.42%0.27
Government0.00%
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Glaxosmi. Pharma | ₹2,514.30 | 44.27 | 42,594 | 2.27% | 278 | +5.70% | 995 | +2.15% | 61.41% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013nseFinancial Year 2013bse
Concall transcripts23
TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024TranscriptAug 2024TranscriptMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptMar 2023TranscriptAug 2022PPTAug 2022PPTAug 2021PPTFeb 2020
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 JulBoard Meeting Intimation for Approve And Take On Record The Un-Audited Financial Results For The First Quarter Ended 30Th June 2026. 21 Jul - Board meets on 3 August 2026 to approve Q1 FY2026-27 unaudited results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 JulShareholder Meeting / Postal Ballot-Outcome of AGM 30 JunShareholder Meeting / Postal Ballot-Scrutinizer''s Report 30 Jun